אורקורט
taro international ltd, israel - triamcinolone acetonide - פסטה - triamcinolone acetonide 0.1 % - triamcinolone - triamcinolone - indicated for the adjunctive treatment and the temporary relief of symptoms associated with oral inflammatory and ulcerative lesions.
אורוקורט e
taro pharmaceutical industries ltd - lidocaine hydrochloride monohydrate; triamcinolone acetonide - פסטה - lidocaine hydrochloride monohydrate 3 g / 100 g; triamcinolone acetonide 0.1 g / 100 g - triamcinolone - triamcinolone - adjunctive treatment and temporary relief of symptoms associated with inflammatory lesions in the oral cavity.
מרוקן
taro pharmaceutical industries ltd - macrogols; potassium chloride; sodium bicarbonate; sodium chloride - אבקה להכנת תמיסה - macrogols 315.0 g; potassium chloride 1.1175 g; sodium bicarbonate 4.2840 g; sodium chloride 8.4240 g - mineral salts in combination - mineral salts in combination - bowel cleansing prior to colonoscopy and barium enema x-ray examinations.
נורמלקס קידס
taro pharmaceutical industries ltd - polyethylene glycol 3350 - אבקה להכנת תמיסה - polyethylene glycol 3350 4 g - macrogol
בסרמי 250 מקג 0.5 מל
aop orphan pharmaceuticals israel ltd, israel - ropeginterferon alfa-2b - תמיסה להזרקה - ropeginterferon alfa-2b 500 mcg/ml - ropeginterferon alfa-2b
בסרמי 500 מקג 0.5 מל
aop orphan pharmaceuticals israel ltd, israel - ropeginterferon alfa-2b - תמיסה להזרקה - ropeginterferon alfa-2b 1000 mcg/ml - ropeginterferon alfa-2b
ריברוקסבן תרו 15 מג
taro pharmaceutical industries ltd - rivaroxaban - טבליות מצופות פילם - rivaroxaban 15 mg - rivaroxaban
ריברוקסבן תרו 20 מג
taro pharmaceutical industries ltd - rivaroxaban - טבליות מצופות פילם - rivaroxaban 20 mg - rivaroxaban
ריברוקסבן תרו 2.5 מג
taro pharmaceutical industries ltd - rivaroxaban - טבליות מצופות פילם - rivaroxaban 2.5 mg - rivaroxaban
מיקובוטין
pfizer pfe pharmaceuticals israel ltd - rifabutin - קפסולות - rifabutin 150 mg - rifabutin - rifabutin - for the treatment of chronic tuberculosis where there is evidence of acid fast bacteria resistant to rifampicin or to two other alternative drugs. for the treatment of infections caused by mac or other atypical mycobacteria where there is evidence of resistant bacteria as above. for the treatment of infections caused by mac or other atypical mycobacteria in aids patients in all cases not subject to the above restrictions. for prevention of mac infections in aids patients whose cd4 counts lower or eqval to 200/mm3